Indications: A third generation parenteral cephalosporin with enhanced activity against pseudomonas aeroginosa.
FDA labeled indications
Bacterial meningitis
Bacterial septicemia
Cystic fibrosis - Pneumonia due to Pseudomonas
Female genital infection
Infection of bone - Infectious disorder of joint
Infection of skin AND/OR subcutaneous tissue
Infectious disease of abdomen
Lower respiratory tract infection
Urinary tract infectious disease
Pharmacology-Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin binding protein 3 (PBP3). A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the gram-negative organisms Pseudomonas and Enterobacteriaceae. Its activity against Pseudomonas is a distinguishing feature of ceftazidime among the cephalosporins
Contra Indications:
Hypersensitivity to cephalosporins.
Precautions:
Allergy to penicillin, renal failure, gastrointestinal disease.
Pregnancy Status:
Category "B"
Lactation Status:
UnSafe
Interactions:
Avoid concomitant use with aminoglycoside and loop diuretics.
Adverse Effects:
Diarrhea, skin reaction, hepatic impairments.
Dosage
Dosage, Adult (usual)
Bacterial meningitis: 2 g IV every 8 hr
Bacterial septicemia: very severe life-threatening infections, especially in immunocompromised; 2 g IV every 8 hr
Cystic fibrosis - Pneumonia due to Pseudomonas: 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Cystic fibrosis - Pneumonia due to Pseudomonas: very severe life-threatening infections, especially in
immunocompromised; 2 g IV every 8 hr
Female genital infection: 2 g IV every 8 hr
Infection of bone - Infectious disorder of joint: 2 g IV every 12 hr
Infection of bone - Infectious disorder of joint: very severe life-threatening infections, especially in
immunocompromised; 2 g IV every 8 hr
Infection of skin AND/OR subcutaneous tissue: mild, 0.5 g to 1 g IV/IM every 8 hr
Infection of skin AND/OR subcutaneous tissue: severe life-threatening infections, 2 g IV every 8 hr
Infectious disease of abdomen: 2 g IV every 8 hr
Lower respiratory tract infection: very severe life-threatening infections, especially in immunocompromised; 2 g IV every 8 hr
Lower respiratory tract infection: uncomplicated pneumonia, 0.5 g to 1 g IV/IM every 8 hr
Urinary tract infectious disease: uncomplicated, 250 mg IV/IM every 12 hr
Urinary tract infectious disease: complicated, 500 mg IV/IM every 8 to 12 hr
Dosage, Pediatric, (usual)
Bacterial septicemia: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Bacterial septicemia: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Cystic fibrosis - Pneumonia due to Pseudomonas: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Cystic fibrosis - Pneumonia due to Pseudomonas: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Female genital infection: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Female genital infection: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Infection of bone - Infectious disorder of joint: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Infection of bone - Infectious disorder of joint: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Infection of skin AND/OR subcutaneous tissue: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Infection of skin AND/OR subcutaneous tissue: 1 month - 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Infectious disease of abdomen: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Infectious disease of abdomen: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Lower respiratory tract infection: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Lower respiratory tract infection: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Urinary tract infectious disease: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Urinary tract infectious disease: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Renal Failure Doses:
Creatinine Clearance Recommended
(mL/min) Dose Frequency
31 to 50 1 g Q12H
16 to 30 1 g Q24H
6 to 15 500 mg Q24H
less than 5 500 mg Q48H
For Dialysis Patiebnts:
Load with 1 gm then 1 gm after each dialysis
Data sources include Micromedex™ (updated Aug 11th, 2011), Cerner Multum™ (updated Aug 10th, 2011), Wolters Kluwer™ (updated Aug 2nd, 2011) and others.Drugsbank.ca
FDA labeled indications
Bacterial meningitis
Bacterial septicemia
Cystic fibrosis - Pneumonia due to Pseudomonas
Female genital infection
Infection of bone - Infectious disorder of joint
Infection of skin AND/OR subcutaneous tissue
Infectious disease of abdomen
Lower respiratory tract infection
Urinary tract infectious disease
Pharmacology-Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin binding protein 3 (PBP3). A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the gram-negative organisms Pseudomonas and Enterobacteriaceae. Its activity against Pseudomonas is a distinguishing feature of ceftazidime among the cephalosporins
Contra Indications:
Hypersensitivity to cephalosporins.
Precautions:
Allergy to penicillin, renal failure, gastrointestinal disease.
Pregnancy Status:
Category "B"
Lactation Status:
UnSafe
Interactions:
Avoid concomitant use with aminoglycoside and loop diuretics.
Adverse Effects:
Diarrhea, skin reaction, hepatic impairments.
Dosage
Dosage, Adult (usual)
Bacterial meningitis: 2 g IV every 8 hr
Bacterial septicemia: very severe life-threatening infections, especially in immunocompromised; 2 g IV every 8 hr
Cystic fibrosis - Pneumonia due to Pseudomonas: 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Cystic fibrosis - Pneumonia due to Pseudomonas: very severe life-threatening infections, especially in
immunocompromised; 2 g IV every 8 hr
Female genital infection: 2 g IV every 8 hr
Infection of bone - Infectious disorder of joint: 2 g IV every 12 hr
Infection of bone - Infectious disorder of joint: very severe life-threatening infections, especially in
immunocompromised; 2 g IV every 8 hr
Infection of skin AND/OR subcutaneous tissue: mild, 0.5 g to 1 g IV/IM every 8 hr
Infection of skin AND/OR subcutaneous tissue: severe life-threatening infections, 2 g IV every 8 hr
Infectious disease of abdomen: 2 g IV every 8 hr
Lower respiratory tract infection: very severe life-threatening infections, especially in immunocompromised; 2 g IV every 8 hr
Lower respiratory tract infection: uncomplicated pneumonia, 0.5 g to 1 g IV/IM every 8 hr
Urinary tract infectious disease: uncomplicated, 250 mg IV/IM every 12 hr
Urinary tract infectious disease: complicated, 500 mg IV/IM every 8 to 12 hr
Dosage, Pediatric, (usual)
Bacterial septicemia: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Bacterial septicemia: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Cystic fibrosis - Pneumonia due to Pseudomonas: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Cystic fibrosis - Pneumonia due to Pseudomonas: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Female genital infection: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Female genital infection: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Infection of bone - Infectious disorder of joint: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Infection of bone - Infectious disorder of joint: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Infection of skin AND/OR subcutaneous tissue: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Infection of skin AND/OR subcutaneous tissue: 1 month - 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Infectious disease of abdomen: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Infectious disease of abdomen: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Lower respiratory tract infection: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Lower respiratory tract infection: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Urinary tract infectious disease: neonates (0 to 4 weeks), 30 mg/kg IV every 12 hr
Urinary tract infectious disease: 1 month to 12 years, 30 to 50 mg/kg IV every 8 hr; MAX 6 g/day
Renal Failure Doses:
Creatinine Clearance Recommended
(mL/min) Dose Frequency
31 to 50 1 g Q12H
16 to 30 1 g Q24H
6 to 15 500 mg Q24H
less than 5 500 mg Q48H
For Dialysis Patiebnts:
Load with 1 gm then 1 gm after each dialysis
Data sources include Micromedex™ (updated Aug 11th, 2011), Cerner Multum™ (updated Aug 10th, 2011), Wolters Kluwer™ (updated Aug 2nd, 2011) and others.Drugsbank.ca
Anda baru saja membaca artikel yang berkategori Ceftazidime adverse effects /
Ceftazidime dosage /
Ceftazidime indication /
Ceftazidime pharmacology
dengan judul Ceftazidime Indications Pharmacology Interactions and Adverse Effects. Anda bisa bookmark halaman ini dengan URL https://medipub.blogspot.com/2011/08/ceftazidime-indications-pharmacology_18.html. Terima kasih!
Ditulis oleh:
Unknown - Thursday 18 August 2011
